Market Overview

CorMedix Receives Minutes from Neutrolin Pre-IND Meeting with FDA


CorMedix (NYSE MKT: CRMD) today announced receipt of the official minutes from the Nov. 14, 2013 Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA).  The minutes confirmed the guidance received from the FDA concerning the development of Neutrolin. CorMedix intends to work with the FDA to finalize a clinical protocol and file an IND to support activities required to commercialize Neutrolin in the U.S.

See full press release

Posted-In: News Guidance Contracts FDA Management Global Movers


Related Articles (CRMD)

View Comments and Join the Discussion!